Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA
China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...
Antengene
Antengene’s ATG-017 Gets FDA Approval for Phase I Clinical Study
Antengene Corporation has announced receiving approval from the US Food and Drug Administration (FDA) to...
Antengene’s Xpovio Receives Taiwan FDA Approval for Multiple Indications
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan...
Antengene’s ATG-101 Receives Orphan Drug Designation for Pancreatic Cancer
China-based biotech Antengene Corp., Ltd (HKG: 6996) has announced that its pipeline candidate ATG-101, a...
Antengene Expands to Australia with New Melbourne Office
China-based biotech firm Antengene (HKG: 6996) announced the opening of its new office in Melbourne,...
Antengene and Celularity Partner on Bispecific Antibody and NK Cell Therapy Combo
China-based Antengene Corporation Ltd (HKG: 6996) announced a preclinical partnership with U.S. firm Celularity Inc....
Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma
China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc....
Antengene Receives Australian TGA Approval for ATG-018 Clinical Trial
China-based biopharma Antengene Corporation (HKG: 6996) has announced receiving approval from the Therapeutic Goods Administration...